Connect with us

Technology

Cancer Registry Software Market size is set to grow by USD 97.1 million from 2024-2028, Growing prevalence of cancer cases to boost the market growth, Technavio

Published

on

NEW YORK, July 17, 2024 /PRNewswire/ — The global cancer registry software market size is estimated to grow by USD 97.1 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  12.75%  during the forecast period.  Growing prevalence of cancer cases is driving market growth, with a trend towards increasing clinical research for oncology. However, data privacy and security concerns poses a challenge. Key market players include CDC, Conduent Inc., Elekta AB, ERS Inc., Inspirata Inc., International Association of Cancer Registries, International Business Machines Corp., McKesson Corp., NeuralFrame Inc., OMH HealthEdge Holdings LLC, Onco Inc., Ordinal Data Inc., Redsson Ltd., Siemens AG, and University of Utah Health.

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

End-user (Government and third party, Pharma
biotech and medical device companies, Hospitals
and medical practice, Private payers, and
Research institutes), Type (Stand-alone software
and Integrated software), and Geography (North
America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

CDC, Conduent Inc., Elekta AB, ERS Inc.,
Inspirata Inc., International Association of Cancer
Registries, International Business Machines Corp.,
McKesson Corp., NeuralFrame Inc., OMH
HealthEdge Holdings LLC, Onco Inc., Ordinal Data
Inc., Redsson Ltd., Siemens AG, and University of
Utah Health

Key Market Trends Fueling Growth

Pharmaceutical and biopharmaceutical companies, along with research institutes, prioritize clinical trials to discover new cancer treatment methods. These trials enable medical professionals to assess treatment efficacy and identify potential diagnoses. Randomized clinical trials (RCTs) facilitate comparing care approaches and treatment options, supporting informed clinical decisions. Population-based and hospital-based cancer registries offer access to comprehensive data for researchers and healthcare providers. This data is crucial for recruiting large patient groups and analyzing causes and cures during clinical research. Advanced cancer registry software enhances data quality, improving clinical research and healthcare evaluation. Consequently, the growth of the cancer registry software market is anticipated during the forecast period. 

The Cancer Registry Software Market is witnessing significant growth due to the increasing incidence of cancer and the need for effective population health management. Software solutions are essential for tracking cancer-specific outcomes, including cancer deaths, prevalence, and staging. These systems help medical professionals capture and exchange health information data for coordinated care and chronic disease management. Cancer Registry Software is vital for hospitals and healthcare organizations to meet healthcare quality goals and adopt Electronic Health Records (EHR). Vendors offer customized solutions for specific areas like lung cancer, developmental disabilities, and cognitive capacities. The software facilitates evidence-based medicine through observational studies, data capture systems, and disease registries. Cancer Registry Software also addresses concerns like medical identity theft and supports cancer treatment through chemo, surgery, and supportive therapies. By providing cancer diagnostics and treatment information, these systems contribute to the adoption of evidence-based therapeutics and improved patient care. The Lung Cancer Foundation and other healthcare organizations can leverage these tools to improve healthcare outcomes and advance research in the field. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

Cancer registry software is essential for collecting and maintaining patient demographic information related to cancer, including details on tumor characteristics, stage of disease, treatment, and outcome. Confidentiality is paramount in handling this sensitive data, as disclosure can cause psychological, emotional, and financial harm. Regulatory bodies and organizations are implementing new guidelines and laws to ensure data protection, such as the North American Association for Central Cancer Registries (NAACCR) and the Health Insurance Portability and Accountability Act (HIPAA). However, challenges persist, such as the use of cloud and computer systems for storing and transmitting data, which may result in data alteration or loss. Additionally, evolving technology and increasing cyberattacks in the healthcare industry pose significant security risks. These challenges may hinder the growth of the cancer registry software market during the forecast period. To address these challenges, it is crucial to adhere to established guidelines, invest in secure technology tools, and ensure proper network connectivity. For instance, the NAACCR provides standard guidelines for securing patient data against unauthorized access and release, while the HIPAA and HHS offer federal standards for protecting customer health data. In developing countries, guidance on planning and developing population-based cancer registration is available, but awareness of new laws and guidelines remains a concern. In conclusion, while cancer registry software plays a vital role in managing cancer data, maintaining confidentiality, and adhering to regulatory requirements is crucial to mitigate risks and ensure the effective use of this technology. By addressing challenges related to data security, network connectivity, and regulatory compliance, the cancer registry software market can continue to grow and provide valuable insights for cancer research and patient care.The Cancer Registry Software market is witnessing significant growth due to the rising prevalence of cancer and the increasing adoption of electronic health records (EHR). The market faces challenges in integrating data from various cancer treatments, including chemotherapy, surgery, and supportive therapies, into cancer registries. The need for evidence-based medicine and therapeutics requires seamless data integration and interoperability between healthcare systems. Medical professionals and patients benefit from cancer registries for disease staging, treatment planning, and cancer screenings. Security is a major concern, with data security and security protocols essential for protecting sensitive patient information. The market includes standalone and integrated software solutions for cancer reporting, patient care management, and medical research. The changing landscape of cancer care involves collaboration between hospitals, medical practices, pharmaceutical, biotech, and medical device companies, oncology departments, and research institutes. Cancer registries play a crucial role in improving cancer care and reducing healthcare costs.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This cancer registry software market report extensively covers market segmentation by

End-user 1.1 Government and third party1.2 Pharma biotech and medical device companies1.3 Hospitals and medical practice1.4 Private payers1.5 Research institutesType 2.1 Stand-alone software2.2 Integrated softwareGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Government and third party-  Cancer registry software is essential for government hospitals and third-party agencies to effectively manage and analyze data related to cancer cases. These solutions enable monitoring and tracking of cancer incidence, prevalence, and mortality rates, providing valuable information for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and third-party agencies can target high-risk populations and geographic disparities, as well as emerging cancer types. Additionally, cancer registry software helps improve the quality of cancer care by evaluating adherence to clinical guidelines, benchmarking outcomes, and identifying variations in treatment practices. This data-driven approach will fuel the expansion of the government and third-party segments in the global cancer registry software market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022)  – Download a Sample Report

Learn and explore more about Technavio’s in-depth research reports

The global head and neck cancer treatment market is driven by advancements in targeted therapies and surgical techniques. Key players focus on personalized medicine and innovative drug development to improve patient outcomes and survival rates.

The global cancer biologics market continues to expand with the rise in biopharmaceutical research. Biologics offer targeted therapies with reduced side effects, driving adoption among oncologists worldwide. Emerging biotech firms and established pharmaceutical companies compete to introduce novel biologic treatments.

The global liquid biopsy market is poised for rapid growth, revolutionizing cancer diagnostics. Non-invasive detection methods using circulating tumor DNA and RNA enable early cancer detection and treatment monitoring. Innovations in sequencing technologies and biomarker research drive market expansion, offering promise for personalized oncology care.

Research Analysis

The Cancer Registry Software Market has witnessed significant growth due to the increasing incidence of cancer worldwide. According to the World Health Organization, there were an estimated 19.3 million new cases and 9.9 million deaths from cancer in 2020. With the adoption of Electronic Health Records (EHR) and the push towards evidence-based medicine, there is a growing demand for cancer registry software solutions. These systems help medical professionals track cancer treatment, including chemotherapy, surgery, and supportive treatments, and collect data on cancer-specific outcomes. The software also aids in the management of diagnostic data and post-endoscopic resection records. The market growth is further driven by the need to reduce healthcare costs and improve patient care. A guidance document issued by the National Cancer Institute outlines the importance of maintaining accurate and complete cancer data for research and public health purposes. Patients and medical professionals alike benefit from the use of cancer registry software, as it facilitates better communication and coordination among healthcare providers and enables more effective treatment plans.

Market Research Overview

The Cancer Registry Software market is witnessing significant growth due to the increasing prevalence of cancer and the adoption of electronic health records (EHR) in healthcare systems. The software solutions enable seamless data integration and interoperability, allowing medical professionals to access evidence-based medicine and make informed decisions for cancer treatment. These systems store data on cancer cases, including disease staging, treatment modalities such as chemo, surgery, and supportive therapies, and cancer screenings. Cancer registries play a crucial role in cancer reporting, patient care management, medical research, and clinical studies, leading to improved cancer care and cancer-specific outcomes. The software caters to various types of cancer and supports hospital workflows, coordinated care, and chronic disease management. The changing landscape of healthcare costs, population health management, health information exchange, and disease registries necessitates the use of cancer registry software. However, concerns around data security and security protocols are essential considerations for software vendors. The market includes standalone and integrated software solutions used by research institutes, hospitals, medical practices, pharmaceutical, biotech, and medical device companies, oncology departments, clinics, and other healthcare entities. The software supports cancer patients throughout the course of their disease, from diagnosis to treatment and beyond. Additionally, the software facilitates healthcare quality goals, hospital workflows, and observational studies, allowing for better data capture and management. Despite these benefits, challenges such as medical identity theft and cognitive capacities for using complex software remain.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userGovernment And Third PartyPharma Biotech And Medical Device CompaniesHospitals And Medical PracticePrivate PayersResearch InstitutesTypeStand-alone SoftwareIntegrated SoftwareGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-registry-software-market-size-is-set-to-grow-by-usd-97-1-million-from-2024-2028–growing-prevalence-of-cancer-cases-to-boost-the-market-growth-technavio-302198405.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Reliance Digital Brings Samsung’s Latest Galaxy Z Fold8 Series and Galaxy Z Flip8 to Stores Across India

Published

on

By

Be among the first to own the new Samsung Galaxy Z Fold8 series and Galaxy Z Flip8. Customers can now pre-order the latest Galaxy foldables at Reliance Digital, with EMIs starting at ₹6000/month.

MUMBAI, India, July 25, 2026 /PRNewswire/ — Reliance Digital, India’s leading consumer electronics retailer, today announced the availability of Samsung’s latest generation of foldable smartphones – the Galaxy Z Fold8 Ultra, Galaxy Z Fold8 and Galaxy Z Flip8. Designed to deliver the next evolution of Galaxy AI, powerful performance and iconic foldable innovation, Samsung’s newest line-up is now available across Reliance Digital stores and online.

Built around Samsung’s vision of making AI more intuitive and personal, the new Galaxy foldables combine immersive displays, premium craftsmanship and intelligent experiences that seamlessly adapt to the way users work, create and stay connected.

Leading the line-up is the Galaxy Z Fold8 Ultra, Samsung’s most premium foldable yet. Featuring an expansive 8-inch Dynamic AMOLED 2X main display, a flagship 200MP camera, the latest Snapdragon® 8 Elite Gen 5 for Galaxy processor and a 5,000mAh battery, the device is engineered for users who demand the ultimate in productivity, creativity and entertainment. It is available in Graphite, Cream and Violet Shadow,.

The Galaxy Z Fold8 brings Samsung’s signature foldable experience in a more compact form factor, featuring a 7.6-inch Dynamic AMOLED 2X main display, a redesigned wider cover screen, Galaxy AI-powered multitasking and flagship-grade performance. Customers can choose from Lavender, Graphite and Cream colour options.

Completing the line-up is the Galaxy Z Flip8, Samsung’s most stylish foldable smartphone, designed for users who want flagship performance in a compact, pocket-friendly form. Equipped with a vibrant 6.9-inch Dynamic AMOLED 2X display, an enhanced FlexWindow, a 50MP camera system and Galaxy AI experiences, the Flip8 effortlessly blends fashion with functionality.

Customers can visit their nearest Reliance Digital store to experience the new foldables first-hand with guidance from Reliance Digital’s Tech Dosts, compare models, explore exclusive launch offers and Pre-order the Galaxy device that best fits their lifestyle. The complete Galaxy Z Fold8 series and Galaxy Z Flip8 are also available through Reliance Digital’s online platform, ensuring customers can be among the first to own Samsung’s latest foldable innovations.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/reliance-digital-brings-samsungs-latest-galaxy-z-fold8-series-and-galaxy-z-flip8-to-stores-across-india-302834321.html

Continue Reading

Technology

Weichai’s Five Tech Routes Global Debut: Diverse Paths to a Green, Smart Future

Published

on

By

HANOI, Vietnam, July 25, 2026 /PRNewswire/ — At VEC in Vietnam on July 21, the Shandong Heavy Industry global partners conference & green intelligent products expo opened. Responding to the green transition of global commercial vehicles and heavy equipment, Weichai – with decades of expertise – unveiled five core tech routes: BEV, HEV, PEMFC, alternative-fuel ICE, and ADAS. Through full-chain proprietary control and breakthroughs, it provides efficient, low-carbon, intelligent power solutions to the global market.

Battery electric vehicle powertrain: full-chain deployment and high-efficiency recharging: Weichai masters core battery, motor, and e‑control technologies. Its CT100 battery – for heavy tractors and dump trucks – features integrated design and triple insulation, delivering better reliability, efficiency, safety, and speed. The WMS3200 drive system, tailored for heavy‑truck haulage, boosts efficiency and cuts vehicle power consumption. The WMC‑L/H/B integrated controllers offer stable, efficient control for light trucks, heavy trucks, and buses.

Hybrid electric vehicle powertrain: deep integration and ultra-long range: Weichai covers series, parallel, and series-parallel architectures, deeply integrating engine and e-drive. For urban logistics, the WP2.5T range extender offers quick response and low noise; for long-haul transport, the WP3NNG natural-gas range extender uses a “pure electric for short hauls, range-extended for long hauls” mode, with over 1,000 km combined range, easing range anxiety.

Proton exchange membrane fuel cell: zero-carbon leadership: Weichai has built a full-chain hydrogen energy system covering components, stacks, and systems. The WEF300 fuel cell engine has been deployed in volume in 49-ton heavy-duty trucks, suitable for long-haul and port logistics. The WEFG500 power generation system provides megawatt-class scalable power to support data centers and industrial plants.

Alternative fuel internal combustion engine: diverse clean-energy options and exceptional cost-effectiveness: Modular design enables flexible switching between H₂ and methanol. WP15DI hydrogen ICE peaks at 46.8% thermal efficiency; WP17T methanol ICE targets heavy‑equipment energy use, cuts operating costs, and is mass‑deployed in 130‑ton mining trucks.

Intelligent driving assistance system: vehicle-road-cloud collaboration: Weichai built a vehicle‑road‑cloud full‑stack architecture, with mining autonomous solution for cm‑level docking & obstacle avoidance, and trunk‑line ADAS with intelligent cruise & auto lane‑change, boosting high‑speed safety and economy.

Going forward, Weichai will keep iterating these five tech routes with global partners to advance sustainable manufacturing.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/weichais-five-tech-routes-global-debut-diverse-paths-to-a-green-smart-future-302834548.html

SOURCE Weichai Group

Continue Reading

Technology

Portland General Electric declares dividend

Published

on

By

PORTLAND, Ore., July 24, 2026 /PRNewswire/ — The board of directors of Portland General Electric Company (NYSE: POR) declared a quarterly common stock dividend of $0.55125 per share.

The company’s dividend is evaluated based on capital requirements and financial performance. PGE targets a dividend payout ratio of 60 to 70% over the long term.

The quarterly dividend is payable on or before October 15, 2026, to shareholders of record at the close of business on September 25, 2026.

About Portland General Electric Company
Portland General Electric (NYSE: POR) is an integrated energy company that generates, transmits and distributes electricity to nearly 960,000 customers serving an area of approximately 2 million Oregonians. Since 1889, Portland General Electric (PGE) has been powering economies, delivering safe, affordable and reliable electricity while working to transform energy systems to meet evolving customer needs. PGE continues to make progress towards emissions reduction targets, and customers have set the standard for prioritizing clean energy with the No. 1 voluntary renewable energy program in the country. PGE is ranked a top ten utility in the 2025 Forrester U.S. Customer Experience Index. In 2025, PGE employees and retirees volunteered over 18,300 hours to more than 400 nonprofits organizations. Through the PGE Foundation, along with corporate contributions and the employee matching gift program, more than $5 million was directed to charitable organizations supporting economic growth and community resilience across our service area. For information: portlandgeneral.com/news.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions about the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed or implied in any forward-looking statement. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

Forward-looking statements include statements, other than statements of historical or current fact, regarding the Company’s amount and timing of dividends payable as well as other statements containing words such as “committed to,” “targets,” or similar expressions.

There can be no assurance that future dividends will be declared. The declaration of future dividends is subject to approval of our board of directors and various risks and uncertainties, including, but not limited to: our cash flow and cash needs; the timing or amount of dividends paid; the timing or outcome of various legal and regulatory actions; changes in the Company’s business strategy; increases in capital expenditures; changes in capital and credit market conditions, including volatility of equity markets as well as changes in PGE’s credit ratings and outlook on such credit ratings restrictions on the payment of dividends under existing or future financing arrangements; changes in tax laws relating to corporate dividends; deterioration in our financial condition or results, and those risks, uncertainties, and other factors identified from time-to-time in our filings with the United States Securities and Exchange Commission (SEC), including our annual report on Form 10-K for the year ended December 31, 2025 and subsequent quarterly reports on Form 10-Q. These reports are available through the EDGAR system free-of-charge on the SEC’s website, www.sec.gov and on the Company’s website, investors.portlandgeneral.com. Investors should not rely unduly on any forward-looking statements. The Company assumes no obligation to update or revise any forward-looking statement as a result of new information, future events or other factors.

Media Contact:
Drew Hanson
Corporate Communications
Phone: 503-464-2067

Investor Contact:
Erin Schwartz
Investor Relations
Phone: 503-464-7751

View original content:https://www.prnewswire.com/news-releases/portland-general-electric-declares-dividend-302834503.html

SOURCE Portland General Company

Continue Reading

Trending